Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTEP (Weill Cornell Medicine)
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
01
Overview
CTEP (Weill Cornell Medicine): sourced facts only. name: "Surface plasmon resonance (SPR) further validated two compounds, EABP 02,303 and CTEP, as CD28 binders." [PMID:40774638]; target: "Surface plasmon resonance (SPR) further validated two compounds, EABP 02,303 and CTEP, as CD28 binders." [PMID:40774638]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, NY, NY 10065, USA." [PMID:40774638]
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on CTEP (Weill Cornell Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTEP (Weill Cornell Medicine).